Investor should take a look at Gilead Sciences’ (GILD) forecast
What’s up with Gilead Sciences?
Gilead Sciences (GILD) opened at $81.62, which means the stock is up 0.38% from yesterday’s closing price of 79.95. Today, the company has a high of $81.76 and a low of $79.19. The company has a market cap of $101.04 billion with a 52-week high of $85.97 and a 52-week low of $60.89.
What about the future for Gilead Sciences?
The high forecast for Gilead Sciences is 97.00 while the low is 58.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Gilead Sciences has a weak forecast. A weak forecast is due to the company posting consistent losses in their earning reports. The future outlook does not seem too bright as this could potentially cause the company to file for bankruptcy.. Based on this information GILD seems to be a risky buy.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.